RPRX N Stock Overview
Operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Royalty Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$528.50 |
| 52 Week High | US$586.00 |
| 52 Week Low | US$448.33 |
| Beta | 0.46 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 14.06% |
| 3 Year Change | -32.84% |
| 5 Year Change | n/a |
| Change since IPO | -35.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| RPRX N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -3.4% | -4.3% |
| 1Y | 14.1% | -27.4% | -14.0% |
Return vs Industry: RPRX N exceeded the MX Pharmaceuticals industry which returned -27.4% over the past year.
Return vs Market: RPRX N exceeded the MX Market which returned -14% over the past year.
Price Volatility
| RPRX N volatility | |
|---|---|
| RPRX N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in MX Market | 6.0% |
| 10% least volatile stocks in MX Market | 2.6% |
Stable Share Price: RPRX N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine RPRX N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Pablo Legorreta | www.royaltypharma.com |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Royalty Pharma plc Fundamentals Summary
| RPRX N fundamental statistics | |
|---|---|
| Market cap | Mex$294.73b |
| Earnings (TTM) | Mex$22.99b |
| Revenue (TTM) | Mex$45.49b |
9.7x
P/E Ratio4.9x
P/S RatioIs RPRX N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RPRX N income statement (TTM) | |
|---|---|
| Revenue | US$2.27b |
| Cost of Revenue | US$491.91m |
| Gross Profit | US$1.77b |
| Other Expenses | US$628.98m |
| Earnings | US$1.15b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.58 |
| Gross Margin | 78.29% |
| Net Profit Margin | 50.53% |
| Debt/Equity Ratio | 74.2% |
How did RPRX N perform over the long term?
See historical performance and comparisonDividends
3.4%
Current Dividend Yield32%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:46 |
| End of Day Share Price | 2024/11/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Royalty Pharma plc is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Charlie Yang | BofA Global Research |
| Jason Matthew Gerberry | BofA Global Research |